UNSPSC 51181614: Carbimazole

This classification denotes an antithyroid agent with the molecular formula C7H10N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8KQ660G60G, chemically known as 4-imidazoline-1-carboxylic acid, 3-methyl-2-thioxo-, ethyl ester but generally known as carbimazole, which bears US NIH Compound Identifier 31072. European Medicines Agency schedules Carbimazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06127MIG.

UNSPSC 51181614 Carbimazole is a Commodity code covering pharmaceutical products supplied through state and local cooperative purchasing arrangements. State and local governments buy this thyroid-regulating medication — and related generic pharmaceuticals across therapeutic categories — through centralized statewide contracts that establish pricing and supply terms with manufacturers, who then distribute through authorized pharmaceutical wholesalers to hospitals, clinics, correctional facilities, and other public-sector health-care entities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), a multi-state cooperative administered by the Minnesota Department of Administration's Office of State Procurement, is the primary recent issuer, and the structure suggests that other states participating in MMCAP (including Oregon, based on the available RFP) soliciting under this code will follow similar cooperative-purchasing models rather than issuing independent solicitations.

Geographic activity centers on the MMCAP membership region, with Minnesota and Oregon explicitly named in the current RFP. The Minnesota Department of Administration issued an RFP (Solicitation S1070000015802, posted January 20, 2026, response due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across MMCAP participating facilities. Vendors must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen / Cencora, Cardinal Health, Morris & Dickson), and provide pricing in flat-price or net-price formats, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing structure, and the remainder on EDI capability, administrative compliance, and willingness to accept a 3 percent administrative fee. Contract awards are effective July 1, 2026, with a two-year term and optional extensions at MMCAP's discretion.